Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional Prospective Observational Study Assessing APRemilast in psOriatic Arthritis in Real-life Clinical Practice in Greek Healthcare Environment. The "APROACH" Study

NCT03780504 is registered in ClinicalTrials.gov with Genesis Pharma S.A. as lead sponsor.

NCT NCT03780504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03780504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional Prospective Observational Study Assessing APRemilast in psOriatic Arthritis in Real-life Clinical Practice in Greek Healthcare Environment. The "APROACH" Study
Lead sponsor
Genesis Pharma S.A.
Phase
Observational
Overall status
Unknown status
Start date
April 15, 2019
Completion date
December 31, 2022
Enrollment
170 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis